Payment overview · 2025
General Payments
$658.11
36 reported records · 9 companies
Healthcare provider profile · identity verified
Bethany S Pennington
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · INEZ, KY · NPI 1598310450
Verified facts
What the public records show
CMS Open Payments records show Bethany S Pennington received $658.11 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $317.74 | 48.3% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $162.37 | 24.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.21 | 9.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.08 | 5.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.32 | 3.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.17 | 3.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.52 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.56 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $6.14 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $658.11 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $310.84 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $283.28 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $162.37 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.21 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $6.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $4.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 743 | 72 |
| Gabapentin | Gabapentin | 645 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 38 |
| Lisinopril | Lisinopril | 176 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 37 |
| Montelukast Sodium | Montelukast Sodium | 121 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 21 |
| Trazodone Hcl | Trazodone Hcl | 102 | 18 |
| Diazepam | Diazepam | 101 | suppressed |
| Furosemide | Furosemide | 100 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 25 |
| Meloxicam | Meloxicam | 100 | 16 |
| Metformin Hcl | Metformin Hcl | 100 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 14 |
| Ibuprofen | Ibuprofen | 90 | 37 |
| Potassium Chloride | Potassium Chloride | 88 | 20 |
| Methylprednisolone | Methylprednisolone | 82 | 58 |
| Omeprazole | Omeprazole | 82 | 19 |
| Sertraline Hcl | Sertraline Hcl | 76 | 18 |
| Losartan Potassium | Losartan Potassium | 71 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 68 | 12 |
| Ozempic | Semaglutide | 67 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 13 |
| Famotidine | Famotidine | 59 | 13 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 55 | 11 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 12 |
| Ondansetron Odt | Ondansetron | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Prednisone | Prednisone | 46 | 29 |
| Simvastatin | Simvastatin | 46 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 38 |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Anastrozole | Anastrozole | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Fluconazole | Fluconazole | 20 | 14 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Constulose | Lactulose | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $658.11 · 36 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, JOURNAVX, NURTEC ODT, Natroba, OTEZLA, QULIPTA, REPATHA, Spinosad, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error